Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
Pulmonary artery hypertension
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "Pulmonary artery hypertension" in MCE Product Catalog:
4
4 Cited Publications
Target:
Research Areas:
Research Areas:
NPS 2390 is an allosteric antagonist of calcium-sensing receptor (CaSR) and mGluR1/5. NPS 2390 inhibits the PI3K/Akt/mTOR signaling pathway, reduces hypoxia-induced intracellular calcium elevation, decreases the expression of autophagy (autophagy) proteins, regulates the expression of phenotypic marker proteins, and inhibits the proliferation of pulmonary artery smooth muscle cells. NPS 2390 attenuates the endogenous apoptosis (apoptosis) pathway, increases the expression level of Bcl-2, downregulates the expression levels of Bax, cytochrome c and caspase-3, alleviates cerebral edema and improves neurological function in rat models. NPS 2390 can be used in studies related to hypoxic pulmonary hypertension, traumatic brain injury, stroke and pain .
Target:
Research Areas:
Phenamil methanesulfonate, an analog of Amiloride (HY-B0285), is a more potent and less reversible epithelial sodium channel (ENaC) blocker with an IC50 of 400 nM . Phenamil methanesulfonate is also a competive inhibitor of TRPP3 and inhibits TRPP3-mediated Ca 2+ transport with an IC50 of 140 nM in a Ca 2+ uptake assay . Phenamil methanesulfonate is an intriguing small molecule to promote bone repair by strongly activating BMP signaling pathway . Phenamil methanesulfonate is used for the research of cystic fibrosis lung disease .
Cat. No.: HY-P1435
CAS No.: 1435893-78-9
Target:
Research Areas:
Target:
Research Areas:
Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology
17-HDHA is a DHA-derived specialized pro-resolving mediator (SPM). 17-HDHA inhibits NF-κB activation by activating PPARγ and upregulating IκBα, targets FPR2 and Bcl-6, and also acts as a precursor of RvD1 and PD1. 17-HDHA inhibits pulmonary artery smooth muscle cell proliferation, regulates the expression of adiponectin, GLUT-4 and inflammatory cytokines, suppresses IgE production by B cells and promotes antibody secretion. 17-HDHA reduces adipose tissue inflammation, improves insulin sensitivity and glucose tolerance, alleviates pathological processes associated with pulmonary hypertension, and enhances antibody responses and virus neutralizing activity against influenza HA. 17-HDHA can be used in research related to obesity-associated inflammation, insulin resistance, glucose intolerance, pulmonary hypertension and influenza virus infection .
Cat. No.: HY-177948
CAS No.: 3052947-04-0
Research Areas:
GRK2 degrader-1 (compound 1) is a potent and orally active GRK2 degrader. GRK2 degrader-1 degrades GRK2 via the ubiquitin-proteasome pathway. GRK2 degrader-1 inhibits right ventricular remodeling and elevation of pulmonary artery pressure in a pulmonary artery hypertension (PAH) mouse model. GRK2 degrader-1 can be used for PAH research .
Cat. No.: HY-106861
CAS No.: 135244-62-1
Target:
Research Areas:
NIP-121 is a new type of potassium channel opener. NIP-121 significantly reduces mean pulmonary artery pressure and total pulmonary resistance through vasodilation. NIP-121 can be used for research on pulmonary arterial hypertension .
Cat. No.: HY-A0096A
CAS No.: 82889-99-4
Synonyms: (Z)-Ciloprost; (Z)-ZK 36374
Target:
Research Areas:
(Z)-Iloprost ((Z)-Ciloprost; (Z)-ZK 36374) is a vasodilator that prevents heparin-induced platelet activation .
Cat. No.: HY-12378A
Target:
Research Areas:
BQ-123 TFA is a potent and selective endothelin A (ETA) receptor antagonist with an IC50 of 7.3 nM and a Ki of 25 nM. BQ-123 TFA inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension .
Cat. No.: HY-W040167
CAS No.: 787582-98-3
Target:
Research Areas:
VPC 23153 is a S1P4 receptor agonist and vasoconstrictor. VPC 23153 activates the S1P4 receptor, thereby triggering vasoconstriction. VPC 23153 induces pulmonary artery contraction. VPC 23153 can be used in studies related to pulmonary arterial hypertension .
Cat. No.: HY-P1435A
Target:
Research Areas:
Synonyms: U-63557A
Target:
Research Areas:
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .
Cat. No.: HY-106080
CAS No.: 85666-24-6
Synonyms: U-63557A free acid
Target:
Research Areas:
Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate is being developed as an antiplatelet agent .
Cat. No.: HY-106080AR
CAS No.: 85666-17-7
Synonyms: U-63557A (Standard)
Research Areas:
Furegrelate (sodium) (Standard) is the analytical standard of Furegrelate (sodium). This product is intended for research and analytical applications. Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .
Cat. No.: HY-183644
Target:
Research Areas:
LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension .
Cat. No.: HY-180585
Research Areas:
LOXL2/sGC modulator-2 (Compound 9k) is a selective and orally active lysyl oxidase-like 2 (LOXL2) and soluble guanylate cyclase (sGC) dual-target regulator. LOXL2/sGC modulator-2 shows inhibitory activity for LOXL2 with an IC50 of 0.1 μM and can activate sGC. LOXL2/sGC modulator-2 can ameliorate vascular remodeling and reduce pulmonary artery pressure. LOXL2/sGC modulator-2 can downregulate PKG1, PCNA, α-SMA, collagen I and fibronectin levels. LOXL2/sGC modulator-2 can be used for the research of pulmonary arterial hypertension .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
